Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Synovial Sarcoma, X Breakpoint 2 (SSX2) (Middle Region) Peptide

SSX2 Reactivité: Humain Hôte: Synthetic BP, WB
N° du produit ABIN2184613

Aperçu rapide pour Synovial Sarcoma, X Breakpoint 2 (SSX2) (Middle Region) Peptide (ABIN2184613)

Antigène

SSX2 (Synovial Sarcoma, X Breakpoint 2 (SSX2))

Origine

Humain

Source

  • 2
Synthetic

Application

Blocking Peptide (BP), Western Blotting (WB)
  • Protein Region

    Middle Region

    Séquence

    TFGRLQGISP KIMPKKPAEE G NDSEEVPEAS GPQNDGKELC PPGKPTTS

    Attributs du produit

    This is a synthetic peptide designed for use in combination with anti-SSX2 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.

    Purification

    Purified
  • Indications d'application

    Optimal working dilution should be determined by the investigator.

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Reconstitution

    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.

    Concentration

    1 mg/mL

    Buffer

    Final peptide concentration is 1 mg/mL in PBS.

    Conseil sur la manipulation

    Avoid repeat freeze-thaw cycles.

    Stock

    -20 °C

    Stockage commentaire

    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • Antigène

    SSX2 (Synovial Sarcoma, X Breakpoint 2 (SSX2))

    Sujet

    SSX2 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X,18) translocation characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are probably responsible for transforming activity. Two transcript variants encoding distinct isoforms have been identified for this gene.

    Alias Symbols: CT5.2a, HD21, HOM-MEL-40, SSX

    Protein Size: 223

    Poids moléculaire

    24 kDa

    ID gène

    6757

    NCBI Accession

    NM_175698, NP_783629
Vous êtes ici:
Chat with us!